Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Is ACADIA Pharmaceuticals (NASDAQ:ACAD) Pressing On With Phase 3 After Remlifanserin Narrowly Missed Phase 2?

● The key secondary measure showed a nominal p-value of 0.0077 at 60 mg.

Nitish Kishor | 14 October 2026

What Could Acumen Pharmaceuticals (NASDAQ:ABOS) Investors Learn From the Late-2026 ALTITUDE-AD Readout?

● The trial enrolled 542 participants with early Alzheimer's disease.

Nitish Kishor | 14 October 2026

What Does the Cash Balance of Acumen Pharmaceuticals (NASDAQ:ABOS) Mean Ahead of ALTITUDE-AD Topline Data?

● Management says the balance should fund operations into early 2027.

Nitish Kishor | 14 October 2026

When Will Acumen Pharmaceuticals (NASDAQ:ABOS) Report Topline Data From Its Phase 2 ALTITUDE-AD Alzheimer's Trial?

● The study compares 35 mg/kg and 50 mg/kg doses against placebo over 18 months.

Nitish Kishor | 14 October 2026

How Far Does the Cash Balance of Absci Corporation (NASDAQ:ABSI) Take ABS-201 Toward Its Next Clinical Readouts?

● Management says the balance funds operations into the second half of 2028.

Nitish Kishor | 14 October 2026

Why Does Absci Corporation (NASDAQ:ABSI) Expect Its Cash to Last Into the Second Half of 2028?

● A $100 million offering included a $40 million strategic investment by Eli Lilly.

Nitish Kishor | 14 October 2026

What Should Investors Watch as Abbott Laboratories (NYSE:ABT) Prepares for Third-Quarter Results on 21 October?

● Second-quarter sales were $12.593 billion, up 13.0% reported and 4.8% comparable.

Nitish Kishor | 14 October 2026

What Should Investors Know Before Abbott Laboratories (NYSE:ABT) Reports Third-Quarter 2026 Results on 21 October?

● Second-quarter net sales were $12,593 million, up 13.0% reported and 4.8% comparable.

Nitish Kishor | 14 October 2026
Support

Hi! How can we help you today?

Loading…